Vascular Effects of JAK Inhibitors on Inflamed Endothelial Cells

Study Background and Research Question

Janus kinase (JAK) inhibitors are integral to the management of autoimmune and inflammatory disorders such as rheumatoid arthritis (RA), owing to their targeted modulation of cytokine signaling. However, mounting clinical and mechanistic evidence has raised questions regarding their cardiovascular (CV) safety profile, particularly in patients already at elevated risk due to chronic inflammation. The reference study by Zavoriti and Miossec (ACR Open Rheumatology, 2025) addresses this concern by comparing the effects of several clinically approved JAK inhibitors—namely tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib—on human endothelial cells (ECs) exposed to inflammatory cytokines. The central question is: how do these JAK inhibitors differentially influence endothelial inflammation, procoagulant responses, and cell survival under conditions mimicking the cytokine milieu of RA?

Key Innovation from the Reference Study

This study is among the first to perform a direct, side-by-side comparison of multiple JAK inhibitors—including tofacitinib citrate (CP-690550 citrate)—in primary human ECs subjected to synergistic inflammatory stimulation by TNF and IL-17A. The innovation lies in dissecting not only the anti-inflammatory efficacy but also the nuanced effects on adhesion molecule expression, procoagulant pathways, and endothelial apoptosis. This approach provides mechanistic clarity regarding why certain JAK inhibitors may have divergent vascular safety profiles, a topic of clinical significance given recent regulatory alerts about increased CV risk with some agents.

Methods and Experimental Design Insights

The investigators used human vascular ECs cultured in vitro, stimulating them with tumor necrosis factor (TNF) and interleukin-17A (IL-17A) to recapitulate the pathogenic cytokine environment relevant to RA. Each JAK inhibitor was applied at 1 μM and 10 μM, reflecting concentrations achievable in pharmacologic and suprapharmacologic contexts. Key readouts included:

• Measurement of IL-6 and IL-8 secretion via ELISA, as surrogates for inflammatory activation
• Quantification of adhesion molecule (VCAM-1, ICAM-1, E-selectin) mRNA by qRT-PCR to assess endothelial leukocyte recruitment potential
• Assessment of coagulation and fibrinolysis factors such as tissue factor and thrombomodulin
• Annexin V staining to detect endothelial apoptosis and cytotoxicity

By systematically evaluating these endpoints across six JAK inhibitors, the study yielded a comprehensive comparative profile of drug effects under inflammatory stress.

Core Findings and Why They Matter

Several key observations emerged from this comparative investigation (reference study):

• Anti-inflammatory effects: All JAK inhibitors, including tofacitinib citrate, reduced IL-6 secretion in ECs stimulated with TNF+IL-17A, indicating broad suppression of cytokine-driven inflammation. Only baricitinib and fedratinib consistently reduced IL-8 production at 1 μM, highlighting subtle differences in chemokine modulation.
• Adhesion molecule regulation: At 1 μM, fedratinib inhibited VCAM-1 and E-selectin upregulation, while tofacitinib specifically attenuated ICAM-1 and E-selectin induction. Notably, at the higher 10 μM dose, most JAK inhibitors (including tofacitinib) paradoxically enhanced VCAM-1 and ICAM-1 expression in the presence of TNF+IL-17A, suggesting potential pro-inflammatory or compensatory effects at supratherapeutic concentrations.
• Coagulation pathway modulation: Peficitinib and fedratinib at both concentrations reduced tissue factor induction, whereas ruxolitinib's effect was limited to 1 μM. None of the JAK inhibitors prevented the downregulation of the anticoagulant molecule thrombomodulin, indicating an incomplete endothelial protective profile.
• Cytotoxicity and apoptosis: Peficitinib and fedratinib exhibited direct cytotoxic and proapoptotic effects on ECs, which could have important implications for endothelial integrity and vascular risk.

The overall conclusion is that while all JAK inhibitors reduce inflammatory cytokine production in ECs, their capacity to modulate adhesion molecule expression and coagulant factors is incomplete and highly variable. These findings provide a mechanistic rationale for observed clinical heterogeneity in cardiovascular risk among different JAK inhibitors.

Comparison with Existing Internal Articles

Recent internal resources have explored complementary aspects of JAK inhibitor biology in immune regulation research. For instance, "Tofacitinib Citrate in JAK-STAT Signaling: Assay Innovation & Insight" and "Precision in Immune Regulation" detail the molecular selectivity and workflow integration of tofacitinib citrate in modulating JAK-STAT signaling. However, the present reference study uniquely advances the field by directly comparing vascular effects of multiple JAK inhibitors under inflammatory stress, rather than focusing solely on immunological endpoints. The article "JAK Inhibitors and Endothelial Dysfunction Under Inflammatory Stress" offers a synthesis of these comparative vascular findings, reinforcing the importance of considering both anti-inflammatory efficacy and endothelial safety in experimental design. Together, these resources emphasize the need for precise selection and dosing of JAK inhibitors in translational and preclinical models, particularly where vascular endpoints or inflammatory disorder research is involved.

Limitations and Transferability

While the study provides critical mechanistic insights, several limitations temper the direct translation to clinical practice. The in vitro model, though valuable for dissecting cell-intrinsic effects, does not capture the full complexity of in vivo hemodynamics, immune cell interactions, or chronic dosing regimens. The use of 10 μM concentrations, while informative for off-target or supratherapeutic effects, exceeds typical plasma levels achieved in patients. Additionally, the study did not examine long-term outcomes such as endothelial repair or regeneration. Thus, while the data strongly inform cardiovascular safety hypotheses, further in vivo and clinical investigations are warranted to validate these findings in disease-relevant settings.

Protocol Parameters

• Cytokine stimulation: Human vascular endothelial cells were treated with TNF (10 ng/mL) and IL-17A (10 ng/mL) to induce a proinflammatory state.
• JAK inhibitor dosing: Tofacitinib citrate, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib were applied at 1 μM and 10 μM concentrations for 24 hours to assess dose-dependent effects.
• Readouts: IL-6 and IL-8 measured by ELISA; VCAM-1, ICAM-1, E-selectin, tissue factor, and thrombomodulin quantified by qRT-PCR; apoptosis assessed by Annexin V staining.
• Practical workflow suggestion: For immune regulation or inflammatory disorder research, start with 10–100 nM tofacitinib citrate as recommended by the product information, optimizing dosing for your cell type and readout sensitivity.

Research Support Resources

For researchers aiming to model JAK-STAT pathway modulation or investigate endothelial and immune cell responses under inflammatory conditions, Tofacitinib citrate (CP-690550 citrate) (SKU A4135) is a well-characterized selective JAK3 inhibitor suitable for in vitro and in vivo studies. Its documented selectivity profile and solubility properties facilitate precise experimental control. Additional mechanistic discussion and troubleshooting strategies are available in referenced internal articles, supporting robust assay design for immune regulation and vascular inflammation research. APExBIO provides high-purity reagents and technical information to enable reproducible workflows in this domain.